The introduction of glucagon-like peptide-1 (GLP-1) receptor agonists, equivalent to semaglutide (Ozempic and Wegovy) is a breakthrough within the administration of weight problems. These drugs have confirmed to be very efficient in selling weight reduction and bettering blood sugar ranges.
Whereas lots of people might imagine that I’ve one thing in opposition to GLP-1s – whether or not as a result of they’re ‘competitors’ for my observe (they aren’t), or that perhaps I don’t agree with utilizing prescription drugs over weight-reduction plan for weight reduction. I wrote all about that right here.
I imagine the brand new class of weight reduction drugs are unbelievable instruments that may assist to alter individuals’s lives for the higher. However they aren’t your complete puzzle; they’re solely only a piece, and there are some very actual limitations to their use.
Current analysis suggests that weight problems charges within the US have dropped very barely – from 46% in 2022 to 45.6% in 2023. There was a 700% enhance in using GLP-1 agonist drugs between 2019 and 2023.
Though even a 0.04% change in weight problems charges could point out a common downward development that could be attributed partially to GLP-1 drugs, there are good causes to imagine that these medication is not going to drastically scale back the prevalence of weight problems…a minimum of, not now. However why?
The reply to this query is multifaceted and complex.
Limitations of GLP-1 Drugs in Addressing Inhabitants-Broad Epidemic
Value and Accessibility: These drugs are tremendous costly – as in, over $15,000 a 12 months in some circumstances. It is a large barrier for individuals who can’t afford to pay out of pocket, or who don’t have non-public insurance coverage protection. Even for these with non-public insurance coverage, firms typically cap spending or period for GLP-1 drugs. Whereas some individuals qualify for GLP-1 meds by way of Medicare or Medicaid, many don’t.
A latest listening to of the US Senate Committee on Well being, Schooling, Labor, and Pensions revealed that Ozempic prices 15x extra in america than in Germany. Knowledge on affected person discontinuation of GLP-1 receptor agonist drugs is inconclusive, however numbers vary from round 50% inside 3 months to 75% by the two 12 months mark. The explanations for going off the meds embody value, uncomfortable side effects, or gradual weight reduction.
In different phrases, so many individuals who would seemingly profit significantly from these drugs, simply can’t entry them in any respect, or for lengthy sufficient. Entry is decrease for individuals in sure racial and ethnic teams, that are additionally the teams which have the best charges of weight problems (and the bottom entry to healthcare general).
The patents for a number of of those drugs are up in March, 2026, that means that inexpensive generic variations of semaglutide will seemingly be available on the market shortly after that. Will they be rather more inexpensive? Solely time will inform.
Sustainability of Results: Whereas GLP-1 drugs are efficient for weight reduction, analysis means that these drugs are most likely a long-term dedication. For many individuals, their advantages are contingent on continued use. A examine from the STEP 1 trial highlighted that two-thirds of the burden misplaced utilizing semaglutide was regained inside a 12 months after therapy discontinuation. Because the numbers point out, some weight regain is probably going, however that’s not essentially true for everybody.
After I work with shoppers who’re on GLP-1 agonist drugs, we focus not solely on meals, but in addition on relationship with meals and with life-style adjustments equivalent to rising bodily exercise.
Limitations on Efficacy of GLP-1 Agonist Drugs: In keeping with Dr. Spencer Nadolsky, D.O. and Weight problems and Lipid Specialist, these meds do have their limits.
Proper now, the typical is round 20% weight reduction with Tizepatide (Mounjaro). For a 400 pound individual, that will imply 80 kilos misplaced. That individual nonetheless has weight problems.
Along with this, Dr. Nadolsky bolstered the truth that not everybody responds to those drugs.
Root Causes of Weight problems: Weight problems is pushed by complicated components, together with socioeconomic disparities, meals system points, and sedentary life. Conversely, GLP-1 drugs primarily goal processes equivalent to urge for food regulation and insulin sensitivity. These are clearly necessary, however to actually impact change on weight problems charges, there needs to be a complete focus not solely on pharmacology, but in addition public well being interventions. A 2023 overview in Nature Medication proposed that initiatives to handle this problem which have 4 components: informing the general public about vitamin, enabling them to make health-promoting selections, motivating them to make adjustments to their routines and habits, and influencing behaviour through social norms and different strategies.
The overview instructed rising lively transport, rising healthcare payor incentives, bettering entry to and affordability of wholesome meals, limiting availability and media advertising and marketing of high-calorie meals, bettering meals labeling, reformulating meals merchandise to be extra healthful, and rising entry to weight administration packages and bariatric surgical procedure.
Facet Results and Contraindications: Widespread uncomfortable side effects of GLP-1 drugs, equivalent to nausea, vomiting, and gastrointestinal discomfort, can deter adherence. Moreover, these medication are contraindicated for people with sure circumstances, equivalent to kidney illness, sure cancers, and a historical past of pancreatitis.
The Function of Dietary Interventions
GLP-1 drugs are efficient for most individuals, however adjustments in weight-reduction plan do must be a part of their use. Dietary methods can improve the efficacy of therapy whereas supporting long-term well being.
Listed here are some ideas for consuming whereas on a GLP-1 drugs:
Prioritize Protein and Fiber: GLP-1 drugs gradual gastric emptying, selling early satiety. Which means most meals and snacks needs to be nutrient-dense to keep away from nutrient deficiencies and promote general well being. A weight-reduction plan wealthy in lean proteins (e.g., meat and fish, tofu, eggs, Greek yogurt and ricotta, beans and lentils) helps to keep up muscle mass. Getting ~25+ grams of fiber per day from greens, complete grains, and fruits, helps maintain fullness and helps blood sugar management. Don’t sleep on beans or soy meals as a approach to get high-quality protein and fibre in a single place!
Reduce Extremely-Processed Meals: Processed meals excessive in refined carbohydrates, added sugars, and unhealthy fat can counteract the advantages of GLP-1 drugs. I like to recommend specializing in complete, minimally processed meals to enhance general metabolic well being. That additionally means minimizing alcohol and different lower-quality meals to assist maximize vitamins in your weight-reduction plan.
Hydration and Small, Frequent Meals: Individuals on GLP-1 drugs typically expertise nausea, which might be mitigated by staying hydrated and consuming smaller, extra frequent meals. On nauseous days, incorporating meals which can be light on the abdomen, equivalent to soups and smoothies, may help.
Aware Consuming Practices: GLP-1 drugs scale back urge for food, creating a chance to observe conscious consuming. Slowing down throughout meals, savoring meals, and listening to starvation cues may help reinforce wholesome consuming behaviors.
Rising Weight Loss Drugs
Along with current GLP-1 receptor agonists, a number of promising weight reduction drugs are below growth or awaiting approval:
- Orforglipron Eli Lilly is growing Orforglipron, an oral GLP-1 receptor agonist. This remedy may present an alternate for sufferers preferring to not use injectables.
- CagriSema (Cagrilintide/Semaglutide Mixture) Novo Nordisk is advancing this mix remedy, displaying important weight reduction results in early trials.
- Retatrutide Retatrutide is a triple-hormone receptor agonist, with early research reporting substantial weight discount.
- VK2735 Viking Therapeutics is exploring VK2735, an oral remedy with promising preliminary outcomes.
Conclusion
GLP-1 drugs provide important advantages for people scuffling with weight problems, however they don’t seem to be a panacea for the broader epidemics. Addressing these complicated, multifactorial challenges requires a complete method that mixes medical innovation with strong public well being efforts. By integrating dietary methods, selling equitable entry to care, and tackling systemic points, we will make significant progress towards reversing the traits in weight problems.
Are you searching for assist along with your vitamin? I’m taking new shoppers in my 1:1 observe. Get extra data and e book a session right here.
Do you know? I even have a web-based course for vitamin in perimenopause and menopause known as Don’t Sweat It. Get extra data and join right here.
